Paraoxonase 1 polymorphism Q192R affects the pro-inflammatory cytokine TNF-alpha in healthy males

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Lüersen, Kai ^a   Schmelzer, Constance ^a   Boesch Saadatmandi, Christine ^a   Kohl, Christine ^a   Rimbach, Gerald ^a   Döring, Frank ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955705535     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-141     Document Type: Article

References (50)

1. The paraoxonase gene family and atherosclerosis. CJ Ng DM Shih SY Hama N Villa M Navab ST Reddy, Free Radic Biol Med 2005 38 2 153 163 10.1016/j.freeradbiomed.2004.09.035 15607899 (Pubitemid 39656127)
2. The three-gene paraoxonase family: Physiologic roles, actions and regulation. LP Precourt D Amre MC Denis JC Lavoie E Delvin E Seidman E Levy, Atherosclerosis 2011 214 1 20 36 10.1016/j.atherosclerosis.2010.08.076 20934178
3. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. MI Mackness SD Hallam T Peard S Warner CH Walker, Comp Biochem Physiol B 1985 82 4 675 677 10.1016/0305-0491(85)90506-1 3004805
4. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. M Aviram E Hardak J Vaya S Mahmood S Milo A Hoffman S Billicke D Draganov M Rosenblat, Circulation 2000 101 21 2510 2517 10831526 (Pubitemid 30366256)
5. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. AD Watson JA Berliner SY Hama BN La Du KF Faull AM Fogelman M Navab, J Clin Invest 1995 96 6 2882 2891 10.1172/JCI118359 8675659
6. Variation in paraoxonase-1 activity and atherosclerosis. H Soran NN Younis V Charlton-Menys P Durrington, Curr Opin Lipidol 2009 20 4 265 274 10.1097/MOL.0b013e32832ec141 19550323
7. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. DM Shih L Gu YR Xia M Navab WF Li S Hama LW Castellani CE Furlong LG Costa AM Fogelman,, et al. Nature 1998 394 6690 284 287 10.1038/28406 9685159 (Pubitemid 28335041)
8. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. MN Oda JK Bielicki TT Ho T Berger EM Rubin TM Forte, Biochem Biophys Res Commun 2002 290 3 921 927 10.1006/bbrc.2001.6295 11798161 (Pubitemid 34687449)
9. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. A Tward YR Xia XP Wang YS Shi C Park LW Castellani AJ Lusis DM Shih, Circulation 2002 106 4 484 490 10.1161/01.CIR.0000023623.87083.4F 12135950 (Pubitemid 34803695)
10. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. DS Ng T Chu B Esposito P Hui PW Connelly PL Gross, Cardiovasc Pathol 2008 17 4 226 232 10.1016/j.carpath.2007.10.001 18402813 (Pubitemid 351978278)
11. The molecular basis of the human serum paraoxonase activity polymorphism. R Humbert DA Adler CM Disteche C Hassett CJ Omiecinski CE Furlong, Nat Genet 1993 3 1 73 76 10.1038/ng0193-73 8098250 (Pubitemid 23063292)
12. Human PON1, a biomarker of risk of disease and exposure. CE Furlong SM Suzuki RC Stevens J Marsillach RJ Richter GP Jarvik H Checkoway A Samii LG Costa A Griffith,, et al. Chem Biol Interact 187 1-3 355 361
13. Paraoxonase gene polymorphisms, oxidative stress, and diseases. HL Li DP Liu CC Liang, J Mol Med 2003 81 12 766 779 10.1007/s00109-003-0481-4 14551701
14. Ubiquinol-induced gene expression signatures are translated into reduced erythropoiesis and LDL cholesterol levels in humans. C Schmelzer P Niklowitz JG Okun D Haas T Menke F Döring, IUBMB Life 2011 63 1 42 48 10.1002/iub.413 21280176
15. Determinants of paraoxonase activity in healthy adults. C Boesch-Saadatmandi G Rimbach C Schrader BM Kofler CK Armah AM Minihane, Mol Nutr Food Res 54 12 1842 1850
16. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. S Egert S Wolffram A Bosy-Westphal C Boesch-Saadatmandi AE Wagner J Frank G Rimbach MJ Mueller, J Nutr 2008 138 9 1615 1621 18716159
17. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. J Ruiz H Blanche RW James MC Garin C Vaisse G Charpentier N Cohen A Morabia P Passa P Froguel, Lancet 1995 346 8979 869 872 10.1016/S0140-6736(95) 92709-3 7564671
18. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. M Serrato AJ Marian, J Clin Invest 1995 96 6 3005 3008 10.1172/JCI118373 8675673
19. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. JJ Regieli JW Jukema PA Doevendans AH Zwinderman JJ Kastelein DE Grobbee Y van der Graaf, J Am Coll Cardiol 2009 54 14 1238 1245 10.1016/j.jacc.2009.05.061 19778663
20. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. S Turban F Fuentes L Ferlic R Brugada AM Gotto CM Ballantyne AJ Marian, Atherosclerosis 2001 154 3 633 640 10.1016/S0021-9150(00)00495-0 11257264 (Pubitemid 32232160)
21. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. B Mackness MI Mackness S Arrol W Turkie PN Durrington, FEBS Lett 1998 423 1 57 60 10.1016/S0014-5793(98)00064-7 9506841 (Pubitemid 28098579)
22. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. M Aviram S Billecke R Sorenson C Bisgaier R Newton M Rosenblat J Erogul C Hsu C Dunlop B La Du, Arterioscler Thromb Vasc Biol 1998 18 10 1617 1624 9763535 (Pubitemid 28465415)
23. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. S Yla-Herttuala W Palinski ME Rosenfeld S Parthasarathy TE Carew S Butler JL Witztum D Steinberg, J Clin Invest 1989 84 4 1086 1095 10.1172/JCI114271 2794046 (Pubitemid 19247577)
24. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. D Steinberg S Parthasarathy TE Carew JC Khoo JL Witztum, N Engl J Med 1989 320 14 915 924 10.1056/NEJM198904063201407 2648148 (Pubitemid 19101597)
25. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. DK Sanghera N Saha CE Aston MI Kamboh, Arterioscler Thromb Vasc Biol 1997 17 6 1067 1073 9194756 (Pubitemid 27260325)
26. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. MD Tobin PS Braund PR Burton JR Thompson R Steeds K Channer S Cheng K Lindpaintner NJ Samani, Eur Heart J 2004 25 6 459 467 10.1016/j.ehj.2003.11.014 15039125 (Pubitemid 38524270)
27. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. R Lakshmy D Ahmad RA Abraham M Sharma K Vemparala S Das KS Reddy D Prabhakaran, Indian J Med Res 131 522 529
28. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. A Gluba T Pietrucha M Banach G Piotrowski J Rysz, Angiology 61 2 157 165
29. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. M Odawara Y Tachi K Yamashita, J Clin Endocrinol Metab 1997 82 7 2257 2260 10.1210/jc.82.7.2257 9215303 (Pubitemid 27287594)
30. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. T Zama M Murata Y Matsubara K Kawano N Aoki H Yoshino G Watanabe K Ishikawa Y Ikeda, Arterioscler Thromb Vasc Biol 1997 17 12 3565 3569 9437206 (Pubitemid 28028569)
31. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Y Imai H Morita H Kurihara T Sugiyama N Kato A Ebihara C Hamada Y Kurihara T Shindo Y Oh-hashi,, et al. Atherosclerosis 2000 149 2 435 442 10.1016/S0021-9150(99)00340-8 10729395 (Pubitemid 30145555)
32. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. M Antikainen S Murtomaki M Syvanne R Pahlman E Tahvanainen M Jauhiainen MH Frick C Ehnholm, J Clin Invest 1996 98 4 883 885 10.1172/JCI118869 8770857 (Pubitemid 26293303)
33. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. GI Rice N Ossei-Gerning MH Stickland PJ Grant, Coron Artery Dis 1997 8 11-12 677 682 9472455 (Pubitemid 28031369)
34. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. SM Herrmann H Blanc O Poirier D Arveiler G Luc A Evans P Marques-Vidal JM Bard F Cambien, Atherosclerosis 1996 126 2 299 303 10.1016/0021-9150(96)05917-5 8902155 (Pubitemid 26336666)
35. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. D Ombres G Pannitteri A Montali A Candeloro F Seccareccia F Campagna R Cantini PP Campa G Ricci M Arca, Arterioscler Thromb Vasc Biol 1998 18 10 1611 1616 9763534 (Pubitemid 28465414)
36. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. YL Ko YS Ko SM Wang LA Hsu CJ Chang PH Chu NJ Cheng WJ Chen CW Chiang YS Lee, Atherosclerosis 1998 141 2 259 264 10.1016/S0021-9150(98)00179-8 9862174
37. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. T Suehiro Y Nakauchi M Yamamoto K Arii H Itoh N Hamashige K Hashimoto, Int J Cardiol 1996 57 1 69 73 10.1016/S0167-5273(96)02779-9 8960946 (Pubitemid 26388830)
38. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators. C Aubo M Senti J Marrugat M Tomas J Vila J Sala R Masia, Eur Heart J 2000 21 1 33 38 10.1053/euhj.1999.1660 10610741 (Pubitemid 30042666)
39. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. M Wang X Lang L Zou S Huang Z Xu, Atherosclerosis 214 2 377 385
40. No or only population-specific effect of PON1 on human longevity: a comprehensive meta-analysis. A Caliebe R Kleindorp H Blanche L Christiansen AA Puca IM Rea E Slagboom F Flachsbart K Christensen G Rimbach,, et al. Ageing Res Rev 2010 9 3 238 244 10.1016/j.arr.2010.03.003 20362697
41. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. RH Boger, J Nutr 2004 134 10 Suppl 2842S 2847S discussion 2853S 15465797 (Pubitemid 39315233)
42. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. RA Hegele JH Brunt PW Connelly, Arterioscler Thromb Vasc Biol 1995 15 1 89 95 7749820
43. The specific role of chemokines in atherosclerosis. V Braunersreuther F Mach S Steffens, Thromb Haemost 2007 97 5 714 721 17479181 (Pubitemid 46804314)
44. Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. C Zhang W Peng M Wang J Zhu Y Zang W Shi J Zhang J Qin, Gene Ther 17 5 626 633
45. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Y Kumon T Suehiro Y Ikeda K Hashimoto, Life Sci 2003 73 22 2807 2815 10.1016/S0024-3205(03)00704-5 14511766 (Pubitemid 37153355)
46. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. CY Han T Chiba JS Campbell N Fausto M Chaisson G Orasanu J Plutzky A Chait, Arterioscler Thromb Vasc Biol 2006 26 8 1806 1813 10.1161/01.ATV.0000227472. 70734.ad 16709944 (Pubitemid 44305334)
47. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. C Popa LJ van Tits P Barrera HL Lemmers FH van den Hoogen PL van Riel TR Radstake MG Netea M Roest AF Stalenhoef, Ann Rheum Dis 2009 68 6 868 872 10.1136/ard.2008.092171 18635596
48. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. C Liu F Batliwalla W Li A Lee R Roubenoff E Beckman H Khalili A Damle M Kern R Furie,, et al. Mol Med 2008 14 9-10 575 581 18615156
49. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. G Kerekes Z Szekanecz H Der Z Sandor G Lakos L Muszbek I Csipo S Sipka I Seres G Paragh,, et al. J Rheumatol 2008 35 3 398 406 18203326 (Pubitemid 351374411)
50. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. B Mackness D Hine Y Liu M Mastorikou M Mackness, Biochem Biophys Res Commun 2004 318 3 680 683 10.1016/j.bbrc.2004.04.056 15144891 (Pubitemid 38624207)